Fernanda Santos Fernandes

Fernanda Santos Fernandes

Auto-generated profile, based on publicly available information

Fernanda Santos Fernandes

University of Franca, Av. Dr. Armando Salles Oliveira, N. 201, Franca, São Paulo 14404-600, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2020 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
NFNATALIA HELEN FERREIRA
NATALIA HELEN FERREIRA
ARArthur Barcelos Ribeiro
Arthur Barcelos Ribeiro
FRFrancisco Rinaldi-Neto
Francisco Rinaldi-Neto
FFFernanda Santos Fernandes
Fernanda Santos Fernandes
SNSamuel Do Nascimento
Samuel Do Nascimento
DTDenise Crispim Tavares
Denise Crispim Tavares

21 March 2022 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MTMaraine Catarina Tadini
Maraine Catarina Tadini
FFFernanda Santos Fernandes
Fernanda Santos Fernandes
SOSaulo Duarte Ozelin
Saulo Duarte Ozelin
MMMatheus Reis Santos de Melo
Matheus Reis Santos de Melo
AMAna Luiza Mansur
Ana Luiza Mansur
Anderson R. M. De OliveiraAnderson R. M. De Oliveira
Anderson R. M. De Oliveira
Amphotericin B (AmB) has been the gold standard to treat systemic fungal infections. The use of AmB is restricted to hospitals because it poses several risks, mainly risks related to its high nephrotoxicity. Given the importance of this drug in medicine, new therapeutics and AmB formulations with nanotechnological improvements are required and could bring many benefits to patients. A new drug formulation with gastro-resistant coated granules has been proposed. The lipid-based system containing AmB was produced and used as raw material in the granulation/coated process. The new developed formulation (AmB-NP-GR) was characterized by optical microscopy, granulometry, and atomic force microscopy (AFM) after disintegration test. AmB-NP-GR showed granular shape, with most granules measured between 250 and 500 µm (37 ± 7% w/w). The AFM images indicated that the granule formulation should disintegrate in the intestine, to release the lipid-based carriers, making them available for absorption and allowing them to reach the blood circulation. The developed formulation was administered to rats in a single dose of 4.0 or 8.0 mg kg-1 and the pharmacokinetics was studied. The samples were analyzed by liquid chromatography coupled to mass spectrometry. Before the pharmacokinetic studies were conducted, the bioanalytical method was validated according to the EMA guideline and all evaluated parameters agreed with this guideline. The pharmacokinetic results showed that Cmax was similar for both doses and that tmax was reached at 4-12 h for dose of 4.0 mg kg-1 and 4 h for dose of 8.0 mg kg-1. The half-life related to the dose of 8.0 mg kg-1 increased significantly compared to the dose of 4.0 mg kg-1 (an increase of more than 3 times). In addition, the mean residence time related to the dose of 8.0 mg kg-1 was 4 times higher than for the lower dose. The clearance value showed to be higher for the lower dose. Together, these results provide important conclusions for experimental design of other in vivo safety and efficacy studies of AmB-NP-GR.